biotech / news / / TechStartups.com
Neomorph says it has closed a $100 million Series B round led by Deerfield Management.
Neomorph closed a $100 million Series B round led by Deerfield Management with notable biotech investors.
KEY POINTS
- Neomorph's lead program, NEO-811, is now in a first-in-human Phase 1/2 trial for advanced kidney cancer.
- Pharma giants Novo Nordisk, Biogen, and AbbVie have partnered with Neomorph across multiple therapeutic areas.
- Neomorph's platform uses molecular glue degraders to target historically 'undruggable' disease-causing proteins.
- Upcoming clinical readouts from NEO-811 will be the first major tests of Neomorph's technology in patients.
COMPANIES
Summarized by Newsio from TechStartups.com. How we summarize →